During follow-up, Group A patients received significantly more subsequent, second line and beyond, multiple myeloma treatments (59.6%) than Group DVMP (22.8%); in total, 19 of them were treated with anti-CD38, 15 patients (48.4%) in Group A and 4 patients (30.8%) in Group B (Table S3). This evidence concerns the gene CD38 and plasma cell myeloma.